Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 3/2016

Open Access 01-06-2016 | B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas

Authors: Sally F. Barrington, N. George Mikhaeel

Published in: Current Hematologic Malignancy Reports | Issue 3/2016

Login to get access

Abstract

Positron emission tomography (PET)-CT was recommended in updated international guidelines for staging/restaging of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, PET was previously regarded as a research application only. This review concentrates on new publications related to PET in these diseases. In DLBCL, PET appears appropriate for staging using prognostic indices established with CT and baseline PET parameters, e.g. metabolic tumour volume, are prognostic of outcome. Early complete metabolic response (CMR) predicts end-of-treatment CMR with excellent prognosis. Patients without CMR at interim should not have treatment altered, but have a worse prognosis, and patients with other high risk features may need closer monitoring. The end-of-treatment scan is confirmed as the standard for remission assessment using Deauville criteria, which are also predictive for patients undergoing ASCT. In FL, PET is more sensitive for staging than CT but misses bone marrow involvement. PET-CT identifies patients at risk of progression after induction chemotherapy better than CT.
Literature
1.
Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.CrossRefPubMed
2.••
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. International guidelines reporting consensus from major cancer centres and co-operative research groups involved in lymphoma, focusing on the role of PET-CT. CrossRefPubMed
3.••
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. Companion paper to above reference, reporting consensus related to staging and response assessment in lymphoma, introducing new metabolic response categories for PET-CT.
4.
Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164:315–28.CrossRefPubMed
5.
El-Galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90:1041–6.CrossRefPubMed
6.
Bishton MJ, Hughes S, Richardson F, et al. Delineating outcomes of patients with diffuse large B cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis. Br J Haematol. 2016;172:246–54.CrossRefPubMed
7.
Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.CrossRefPubMed
8.
Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.CrossRefPubMed
9.•
Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 2016. doi:10.​1007/​s00259-016-3315-7. Explored interaction of baseline predictive factors on PET-CT including metabolic tumour volume with early response using Deauville criteria.in 147 consecutive patients treated for DLBCL.
10.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987–94.
11.
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefPubMed
12.
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.CrossRefPubMed
13.
el-Galaly T, Cheah CY, Hutchings M, et al. Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP (−like) therapy. Hematol Oncol. 2015;33:181–243 (abstract 211).CrossRef
14.
Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.CrossRefPubMed
15.
Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed
16.
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMedPubMedCentral
17.
Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.CrossRefPubMedPubMedCentral
18.
Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, Gallamini A, Siegel BA, Cashen AF, Véra P, Tilly H, Versari A, Itti E. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017–22.
19.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Reply to B. Bennani-Baiti et al., H.J.A. Adams et al., E. Laffon et al., and E.A. Hawkes et al. J Clin Oncol. 2015;33:1221–3.CrossRefPubMed
20.
Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41:565–74.CrossRefPubMed
21.
Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244–50.CrossRefPubMed
22.
Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7.CrossRefPubMed
23.
Cerci JJ, Gyorke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591–7.CrossRefPubMed
24.
Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–6.PubMed
25.
Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745–50.CrossRefPubMed
26.
Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76:473–80.CrossRefPubMed
27.
Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7.CrossRefPubMed
28.••
Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33:2523–9. Prospective study in 138 patients with DLBCL evaluating both interim and EOT PET-CT using standardised methods for PET, confirming role of PET for remission assessment.
29.••
Carr R, Fanti S, Paez D, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936–44. Prospective international study in 327 patients with DLBCL reporting outcomes according to interim and EOT scans showing (i) excellent prognosis of patients with early and late CMR, (ii) good outcomes for ‘slow responders’ with interim positive and EOT negative scans and (iii) inferior outcomes for patients with early and late positive PETscans. Confirmed role of PET for remission assessment but advised against intensification of treatment on interim PET to avoid overtreatment of patients.
30.
Cashen AF, Dehdashti F, Luo J, et al. (18)F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386–92.CrossRefPubMedPubMedCentral
31.
Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118:4053–61.CrossRefPubMedPubMedCentral
32.
Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:773–80.CrossRefPubMed
33.
Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73.CrossRefPubMed
34.
Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012;30:184–90.CrossRefPubMed
35.
Yang D-H, Min J-J, Song H-C, et al. Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011;47:1312–8.CrossRefPubMed
36.
Yoo C, Lee DH, Kim JE, et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90:797–802.CrossRefPubMed
37.
Zinzani PL, Gandolfi L, Broccoli A, et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer. 2011;117:1010–8.CrossRefPubMed
38.
Mylam KJ, Kostakoglu L, Hutchings M, et al. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma. 2015;56:2005–12.CrossRefPubMed
39.
Huntington SF, Nasta SD, Schuster SJ, et al. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:2579–84.CrossRefPubMed
40.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.CrossRefPubMed
41.
Strobel K, Schaefer NG, Renner C, et al. Cost-effective therapy remission assessment in lymphoma patients using 2- fluorine-18 fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658–64.CrossRefPubMed
42.
Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15:242–8.CrossRefPubMedPubMedCentral
43.
Pardal E, Coronado M, Martin A, et al. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014;167:327–36.CrossRefPubMed
44.
Swinnen LJ, Li H, Quon A, et al. Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170:56–65.CrossRefPubMed
45.
Duehrsen U, Hüttmann A, Müller S, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. 2014;124:391.
46.
Sehn LH, Hardy ELG, Gill KK, et al. Phase 2 trial of interim pet scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2014;124:392.
47.
Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer. 2008;113:2496–503.CrossRefPubMed
48.
Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant. 2011;46:393–9.CrossRefPubMed
49.
Akhtar S, Al-Sugair AS, Abouzied M, et al. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. Bone Marrow Transplant. 2013;48:551–6.CrossRefPubMed
50.•
Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125:2579–81. Retrospective review of 126 patients with B-NHL undergoing ASCT showing Deauville scores to be predictive of treatment outcomes.
51.
Janikova A, Bolcak K, Pavlik T, et al. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma. 2008;8:287–93.CrossRefPubMed
52.•
Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108–12. Largest study reporting PET for staging FL in 124 patients in a randomised trial, demonstrating PET is more sensitive than CT for nodal and extranodal disease. Confirmed reports that upstaging by PET can change management in significant proportion of patients with limited stage on CT but that PET misses bone marrow involvement in FL.
53.
Scott AM, Gunawardana DH, Wong J, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:347–53.CrossRefPubMed
54.
Wirth A, Foo M, Seymour JF, et al. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2008;71:213–9.CrossRefPubMed
55.
Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med. 1993;329:1608–14.CrossRefPubMed
56.
Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22.CrossRefPubMed
57.
58.
Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–12.CrossRefPubMedPubMedCentral
59.
Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.CrossRefPubMed
60.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed
61.
Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194–200.CrossRefPubMed
62.
Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–22.CrossRefPubMed
63.
Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442–7.CrossRefPubMed
64.••
Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Hematol. 2014;1:e17–27. Pooled analysis of three multicentre studies with 246 patients with FL. Demonstrated PET to be superior to CT-based response assessment after induction chemoimmunotherapy. PET was an independent predictor of PFS compared with CT response and FLIPI. Median PFS was 74 months for patients with CMR on PET but only 16.9 months for patients without CMR. CrossRef
65.
Alcantara M, Dupuis J, Mareschal S, et al. PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. Eur J Nucl Med Mol Imaging. 2015;42:215–21.CrossRefPubMed
Metadata
Title
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas
Authors
Sally F. Barrington
N. George Mikhaeel
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 3/2016
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0318-1

Other articles of this Issue 3/2016

Current Hematologic Malignancy Reports 3/2016 Go to the issue

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

Management of Patients with MYC-Altered Lymphomas

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy

Acute Lymphocytic Leukemias (K Ballen, Section Editor)

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults

Multiple Myeloma (P Kapoor, Section Editor)

Nuances in the Management of Older People With Multiple Myeloma

Acute Lymphocytic Leukemias (K Ballen, Section Editor)

The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits